The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human phase I study of CZ48, a lactone ring protected oral camptothecin, in patients with advanced solid tumors.
Devalingam Mahalingam
No relevant relationships to disclose
Montaser F. Shaheen
No relevant relationships to disclose
John Sarantopoulos
No relevant relationships to disclose
Steven Weitman
No relevant relationships to disclose
Beppino C. Giovanella
Research Funding - Christus Stehlin Foundation
Zhisong Cao
Research Funding - Christus Stehlin Foundation
Douglas Coil
Research Funding - Christus Stehlin Foundation
Constantine Markides
Research Funding - Christus Stehlin Foundation
Lucy Liu
Research Funding - Christus Stehlin Foundation
Claire F. Verschraegen
No relevant relationships to disclose